Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21564)	5/29/1998 12:27:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

LGND gets a little press this a.m. in S&P Personal Wealth. Featured Articles from S&P Personal Wealth NEW YORK, May 29 /PRNewswire/ -- Read the following articles exclusively at S&P Personal Wealth ( personalwealth.com ). Standard & Poor's is a division of the McGraw-Hill Companies: "FDA Advisory Panel Recommends Centocor's Avakine for Approval" personalwealth.com After the close of trading on May 28, an FDA advisory panel recommended for approval Centocor Inc.'s (Nasdaq: CNTO) Avakine drug for treatment of Crohn's disease. Trading in shares of Centocor, a developer of monoclonal antibodies and DNA-based products, was halted all day Thursday pending the panel's decision. Other stocks featured in this morning's MarketMovers include SIBIA Neurosciences (Nasdaq: SIBI), Ligand Pharmaceuticals (Nasdaq: LGND), ICOS Corp. (Nasdaq: ICOS), Ortel Corp. (Nasdaq: ORTL), and American Eagle Outfitters (Nasdaq: AEOS)